AC-1204 Long-term Efficacy Response Trial (ALERT Protocol)

Two primary outcome measures will be assessed in APOE4(-) patients: 1. differences from baseline between AC-1204 and placebo groups' ADAS-cog scores at 6 months 2. differences from baseline between AC-1204 and placebo groups' CIBIC+ scores at 6 months Secondary endpoints will include differences between AC-1204 \& placebo groups' scores for these same instruments at 3 months.